Press Release: EMEA recommends authorisation of first pre-pandemic influenza vaccine

The European Medicines Agency (EMEA), on 21 February 2008, recommended the authorisation of the first 'pre-pandemic vaccine' for humans against influenza caused by the H5N1 virus. Prepandrix from GlaxoSmithKline Biologicals is a pre-pandemic vaccine that is intended to trigger an immune response against the H5N1 strain of the influenza virus before or during an officially declared influenza pandemic, in accordance with official guidance.